Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Investment analysts at HC Wainwright dropped their FY2023 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a research note issued to investors on Thursday, November 16th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($0.56) for the year, down from their prior estimate of ($0.49). HC Wainwright currently has a “Buy” rating and a $4.50 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2023 earnings at ($0.18) EPS, Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.52) EPS.
Unicycive Therapeutics Trading Down 2.0 %
Shares of NASDAQ:UNCY opened at $0.50 on Monday. The business has a 50-day moving average price of $0.70 and a 200 day moving average price of $1.04. The company has a market capitalization of $17.47 million, a price-to-earnings ratio of -0.29 and a beta of 2.64. Unicycive Therapeutics has a 12-month low of $0.40 and a 12-month high of $2.87.
Hedge Funds Weigh In On Unicycive Therapeutics
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
- Five stocks we like better than Unicycive Therapeutics
- Basic Materials Stocks Investing
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 11/13 – 11/17
- 3 Warren Buffett Stocks to Buy Now
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.